Cleveland Clinic Lou Ruvo Center for Brain Health Obtains Sole Investigational New Drug License for GE180 Tracer to Detect Neuroinflammation in the Brains of Those With Parkinson's and Alzheimer's Disease
January 16, 2019
January 16, 2019
LAS VEGAS, Nevada, Jan. 16 -- The Cleveland Clinic issued the following news release:
* * *
- New imaging study is the first to use GE180 in this patient population to better understand the role of inflammation in disease pathology
* * *
The Cleveland Clinic Lou Ruvo Center for Brain Health has obtained the only Investigational New Drug (IND) to be issued by the Federal Drug Administration to test the GE180 ligand tracer, an experimental diagno . . .
* * *
- New imaging study is the first to use GE180 in this patient population to better understand the role of inflammation in disease pathology
* * *
The Cleveland Clinic Lou Ruvo Center for Brain Health has obtained the only Investigational New Drug (IND) to be issued by the Federal Drug Administration to test the GE180 ligand tracer, an experimental diagno . . .